Revenue
2022
2023
2024
2025
Akari Therapeutics Plc (AKTX)
Price$11.47Cached quote
Net income
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $2.8M | $7.0M | $5.5M | $9.6M | $9.1M | $8.8M | $8.7M | $11.8M | $23.3M | $17.3M | $5.8M | $1.6M | $1.3M | $1.5M | $841,000 | $247,000 | — | — | — | — | — |
| Operating expenses | $17.3M | $21.6M | $16.8M | $23.1M | $17.2M | $18.0M | $17.0M | $20.8M | $37.8M | $27.2M | $30.6M | $1.9M | — | — | — | — | — | — | — | — | — |
| Operating income | −$17.3M | −$21.6M | −$16.8M | −$23.1M | −$17.2M | −$18.0M | −$17.0M | −$20.8M | −$37.8M | −$27.2M | −$30.6M | −$1.9M | −$3.6M | −$3.7M | −$2.2M | −$792,000 | — | — | — | — | — |
| EBITDA | −$17.4M | −$21.6M | −$16.8M | −$23.1M | −$17.2M | −$18.0M | −$16.9M | −$20.7M | −$37.7M | −$27.2M | −$30.6M | −$1.9M | −$3.6M | −$3.7M | −$2.2M | −$792,000 | — | — | — | — | — |
| Net income | −$17.3M | −$19.8M | −$10.0M | −$17.7M | −$17.4M | −$17.1M | −$16.8M | −$20.5M | −$35.4M | −$18.1M | −$45.3M | −$1.9M | −$3.6M | −$4.3M | −$2.1M | −$675,000 | −$1.0M | −$1.4M | −$3.1M | −$1.8M | −$2.5M |
| Basic EPSper basic share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.03 | -$0.02 | -$0.05 | -$0.02 | -$0.01 | -$0.03 | -$0.00 | -$0.00 | — | — | — | — | — |
| Diluted EPSper diluted share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.03 | -$0.02 | -$0.05 | -$0.02 | -$0.01 | -$0.03 | -$0.00 | -$0.00 | — | — | — | — | — |
Owners
Reported shareholders
≈5.59%of listed shares
Huh Hoyoung7.82B shares · Nov 14, 2024
View holders
| Holder | % owned |
|---|---|
Huh Hoyoung | ≈5.59%7.82B shares |
Patel Samir Rashmikant | ≈3.81%5.34B shares |
Prudo-Chlebosz Raymond | ≈3.51%4.92B shares |
Patel Sandip I | ≈0.73%1.02B shares |
Gaslightwala Abizer | ≈0.05%71.72M shares |
Neal James R | ≈0.02%32.22M shares |
MMCAP International Inc. SPC | <0.01%100K shares |
Cresset Asset Management, LLC | <0.01%20.56K shares |
JANE STREET GROUP, LLC | <0.01%15.46K shares |
HRT FINANCIAL LP | <0.01%13.75K shares |
IFP Advisors, Inc | <0.01%181 shares |
SBI Securities Co., Ltd. | <0.01%14 shares |
Caitong International Asset Management Co., Ltd | <0.01%8 shares |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | <0.01%7 shares |
Truvestments Capital LLC | <0.01%1 shares |
Percentages use 140.03B shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 16, 2025Form 4 | Neal James RDirector | BuyPre-Funded Warrants to purchase ADRs · derivative | 3.1K | $0.40 | $1.2K | 3.1K |
| Dec 16, 2025Form 4 | Neal James RDirector | BuyWarrants to purchase ADRs · derivative | 3.1K | — | — | 3.1K |
| Dec 16, 2025Form 4 | Neal James RDirector | BuyPre-Funded Warrants to purchase ADRs · derivative | 2.5K | $0.40 | $989.20 | 2.5K |
| Dec 16, 2025Form 4 | Neal James RDirector | BuyWarrants to purchase American Depositary Shares ("ADRs") · derivative | 2.5K | — | — | 2.5K |
| Dec 16, 2025Form 4 | Prudo-Chlebosz RaymondDirector | BuyPre-Funded Warrants to purchase ADRs · derivative | 386.7K | $0.40 | $154.7K | 386.7K |